WallStreetZenWallStreetZen

NASDAQ: BNTC
Benitec Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BNTC

Based on 2 analysts offering 12 month price targets for Benitec Biopharma Inc

Min Forecast
$17.00+53.85%
Avg Forecast
$21.00+90.05%
Max Forecast
$25.00+126.24%

Should I buy or sell BNTC stock?

Based on 2 analysts offering ratings for Benitec Biopharma Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BNTC's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates BNTC as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their BNTC stock forecasts and price targets.

BNTC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-15
lockedlocked$00.00+00.00%2026-05-12

1 of 1

Forecast return on equity

Is BNTC forecast to generate an efficient return?

Company
-22.79%
Industry
-21.61%
Market
150.8%
BNTC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BNTC forecast to generate an efficient return on assets?

Company
-22.35%
Industry
-4.26%
BNTC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BNTC earnings per share forecast

What is BNTC's earnings per share in the next 2 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$1.24
Avg 2 year Forecast
-$1.22

BNTC revenue forecast

What is BNTC's revenue in the next 2 years based on estimates from 9 analysts?

Avg 1 year Forecast
$15.9M
Avg 2 year Forecast
$18.1M

BNTC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BNTC$11.05$21.00+90.05%Buy
GALT$3.73$11.00+194.91%Buy
RCKT$3.41$11.50+237.24%Strong Buy
FENC$10.64$16.67+56.64%Strong Buy
BBOT$4.88$22.00+350.82%Strong Buy
View Top Biotech Stocks

Benitec Biopharma Stock Forecast FAQ

Is Benitec Biopharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BNTC) stock is to Buy BNTC stock.

Out of 2 analysts, 0 (0%) are recommending BNTC as a Strong Buy, 2 (100%) are recommending BNTC as a Buy, 0 (0%) are recommending BNTC as a Hold, 0 (0%) are recommending BNTC as a Sell, and 0 (0%) are recommending BNTC as a Strong Sell.

If you're new to stock investing, here's how to buy Benitec Biopharma stock.

What is BNTC's earnings growth forecast for 2027-2028?

(NASDAQ: BNTC) Benitec Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 64.19%.

Benitec Biopharma's earnings in 2026 is -$48,884,000.On average, 9 Wall Street analysts forecast BNTC's earnings for 2027 to be -$42,516,924, with the lowest BNTC earnings forecast at -$51,847,561, and the highest BNTC earnings forecast at -$36,793,492.

In 2028, BNTC is forecast to generate -$41,785,176 in earnings, with the lowest earnings forecast at -$58,581,010 and the highest earnings forecast at -$21,282,510.

What is BNTC's revenue growth forecast for 2027-2028?

(NASDAQ: BNTC) Benitec Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.87%.

Benitec Biopharma's revenue in 2026 is $0.On average, 9 Wall Street analysts forecast BNTC's revenue for 2027 to be $547,161,478, with the lowest BNTC revenue forecast at $0, and the highest BNTC revenue forecast at $3,942,846,913.

In 2028, BNTC is forecast to generate $622,878,430 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $2,564,722,805.

What is BNTC's forecast return on assets (ROA) for 2027-2028?

(NASDAQ: BNTC) forecast ROA is -22.35%, which is lower than the forecast US Biotechnology industry average of -4.26%.

What is BNTC's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BNTC price target, the average BNTC price target is $21.00, with the highest BNTC stock price forecast at $25.00 and the lowest BNTC stock price forecast at $17.00.

On average, Wall Street analysts predict that Benitec Biopharma's share price could reach $21.00 by Sep 15, 2027. The average Benitec Biopharma stock price prediction forecasts a potential upside of 90.05% from the current BNTC share price of $11.05.

What is BNTC's Earnings Per Share (EPS) forecast for 2027-2028?

(NASDAQ: BNTC) Benitec Biopharma's current Earnings Per Share (EPS) is -$0.01. On average, analysts forecast that BNTC's EPS will be -$1.24 for 2027, with the lowest EPS forecast at -$1.51, and the highest EPS forecast at -$1.07. In 2028, BNTC's EPS is forecast to hit -$1.22 (min: -$1.71, max: -$0.62).

What is BNTC's forecast return on equity (ROE) for 2027-2028?

(NASDAQ: BNTC) forecast ROE is -22.79%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.